← Eichor
Study identifier: NCT07449091 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Adaptability of an Undetectable = Untransmissible Model for HBV

Condition: Chronic Hepatitis b · Viremia  ·  Sponsor: NYU Langone Health

PhaseN/A
Planned participants55
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersYes

About this study

Persons with chronic hepatitis B (HBV) infection and active viremia are infectious and may transmit virus to others through blood/body fluid exposure. Immune tolerant treatment naive persons with hepatitis B infection express anxiety regarding disclosure of their infection status and significant fear of transmission to their partners leading to social isolation and impact on their personal lives. This study will provide data correlating serum and body fluid viral levels in persons with chronic hepatitis B infection not on therapy and those with viral suppression on long-term anti-retroviral therapy (ART) that may support the concept of "Undetectable=Untransmissible" (U=U) in patients with chronic hepatitis B.

This description comes directly from the study's public registry record.

Talk to the study team

AnnMarie Liapakis, MD  ·  212-263-3751  ·  AnnMarie.Liapakis@nyulangone.org

Always discuss trial participation with your own doctor first.

Locations (1)

NYU Langone HealthNew York, New York, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07449091